Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth Second quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and adjusted diluted EPS of $3.12, up 19.1% from 2025 Full year 2026 revenues now expected to be between $11.95 billion and $12.05 billion Full year 2026 reported diluted EPS now expected to be between $9.97 and $10.17; and adjusted diluted EPS expected to be between $11.05 and $11.25 SECAUCUS, N.J. , July 23, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX ), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2026.

Recent Highlights: Serving Customers and Delivering Innovations Continued to advance our Co-Lab Solutions implementation and joint venture laboratory with Corewell Health in Michigan and developed new capabilities in kidney care through our collaboration with Fresenius Medical Care in the United States. Generated robust revenue growth through questhealth.com and our consumer, wearable and wellness partners. Grew revenues by double-digits in several areas of Advanced Diagnostics, including Quest AD-Detect® blood tests for Alzheimer's disease and advanced cardiometabolic and endocrine tests, including liver fibrosis testing. Granted New York State approval for our Haystack MRD® test and became the largest reference lab to utilize Flatiron Health's OncoEMR® Molecular Profiling Integration (MPI) platform for select cancer tests, including Haystack MRD, starting with a pilot with American Oncology Network (AON).

Driving Operational Excellence In the lab, extended automation solutions to improve quality and productivity in cervical cancer screening and front-end specimen processing to additional labs. Outside the lab, launched IntelliDraw™ to guide clinical staff of our physician customers through specimen collection, to enhance quality and the service experience.

Three Months Ended June 30, Six Months Ended June 30, 2026 2025 Change 2026 2025 Change (dollars in millions, except per share data) Reported: Net revenues $ 3,043 $ 2,761 10.2 % $ 5,938 $ 5,413 9.7 % Diagnostic Information Services revenues $ 2,978 $ 2,699 10.3 % $ 5,810 $ 5,288 9.9 % Revenue per requisition (2.8) % (2.1) % Requisition volume 13.1 % 12.0 % Organic requisition volume 13.0 % 11.9 % Operating income (a) $ 459 $ 438 4.6 % $ 858 $ 784 9.4 % Operating income as a percentage of net revenues (a) 15.1 % 15.9 % (0.8) % 14.4 % 14.5 % (0.1) % Net income attributable to Quest Diagnostics (a) $ 320 $ 282 13.4 % $ 572 $ 502 13.9 % Diluted EPS (a) $ 2.84 $ 2.47 15.0 % $ 5.08 $ 4.41 15.2 % Cash provided by operations $ 597 $ 544 9.7 % $ 875 $ 858 1.9 % Capital expenditures $ 138 $ 108 27.0 % $ 252 $ 225 12.1 % Adjusted (a): Operating income $ 502 $ 466 7.8 % $ 949 $ 872 8.8 % Operating income as a percentage of net revenues 16.5 % 16.9 % (0.4) % 16.0 % 16.1 % (0.1) % Net income attributable to Quest Diagnostics $ 350 $ 298 17.3 % $ 631 $ 549 14.9 % Diluted EPS $ 3.12 $ 2.62 19.1 % $ 5.62 $ 4.83 16.4 % (a) For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.

Updated Guidance for Full Year 2026 The company updates its full year 2026 guidance as follo...